Last reviewed · How we verify
GW870086 0.2%
At a glance
| Generic name | GW870086 0.2% |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Test the Effect of 2 Different Doses of Topical GW870086X on Atopic Dermatitis Also Including a Postive Control and a Placebo (PHASE2)
- A Study Assessing GW870086's Potential to Cause Skin Thinning (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GW870086 0.2% CI brief — competitive landscape report
- GW870086 0.2% updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI